Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920021 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
A Phase 2 study, sponsored by AnaptysBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02920021: Completed Phase 2 study, sponsored by AnaptysBio.
NCT02920021 is a Phase 2 study that has completed, run by AnaptysBio. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02920021, a Phase 2 study, has completed, sponsored by AnaptysBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. AEs include any clinical laboratory test results determined to be clinically significant by the investigator. AE was considered "serious" if there was any of the following outcomes: death, life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization
Interventions
- DRUG Placebo
- DRUG Etokimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-01-26 |
| Est. Completion | 2018-03-30 |
| Phase | Phase 2 |
What the finished NCT02920021 record still lists
NCT02920021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02920021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02920021 about?
NCT02920021 is a clinical study titled "Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy". The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.
What is the current status of trial NCT02920021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-01-26. Estimated completion is 2018-03-30.
What interventions are being tested in trial NCT02920021?
The interventions under investigation include: Placebo (DRUG), Etokimab (DRUG).
Who is sponsoring clinical trial NCT02920021?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02920021's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI